In the first installment of our three-part series on the financing landscape for life sciences issuers, we covered the evolution of the typical life sciences IPO. In the second installment, we covered post-IPO financing dynamics and the importance of laying the foundation for successful capital ... >>>Read More
Are the Financing Markets Really Open? – An Examination of the US Equity, Convertible, High Yield, and Investment Grade Markets in Spring 2022
With Federal Reserve tightening and geopolitical uncertainty rising in the last few months, we have seen gains accumulated during COVID dissipate since the start of the year. Consequently, US secondary markets have caused drastic shifts in primary issuance behavior in each of the major financing ... >>>Read More
Convertible 101 for Beginners
As a courtesy for those who may not have prior experience with convertible bonds, we provide some background information on some general questions. What are convertible offerings? Convertible offerings are sales of securities convertible into equity (generally common stock) of public ... >>>Read More
Q1 2022 Convertible Market Review
As part of our market update series, please see the summary below of what we saw in the convertible market in Q1 2022. New Issuance. Q1 2022 saw 11 new issue convertible deals (all debt) with a total volume of $6.1bn, which marks the lowest level of issuance since Q4 2018 ($5.3bn across 16 ... >>>Read More
Q4 2021 Convertible Market Review
As part of our market update series, please see the summary below of what we saw in the convertible market in Q4 2021. New Issuance. Q4 2021 saw 27 new issue convertible deals (all debt) with a total volume of $18.1bn, which brought total 2021 issuance to $92.8bn across 155 deals. 2021 was the ... >>>Read More
- 1
- 2
- 3
- …
- 10
- Next Page »